Arnica Montana Whole Arsenic Trioxide Aviscumine B
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Arnica Montana Whole Arsenic Trioxide Aviscumine B
- Multi-Component Compound (Arnica Montana + 9 Others): Insufficient Data for Repurposing Evaluation
Multi-Component Compound (Arnica Montana + 9 Others): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This candidate consists of a 10-ingredient complex mixture (including Arnica Montana, Arsenic Trioxide, Aviscumine, and others) with no approved indications on record in Taiwan or the United States. The TxGNN model was unable to generate any repurposing predictions for this compound, as it could not be matched to a single DrugBank entity. Without a recognized drug identity or baseline indication, no evidence-based evaluation can be completed at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (Model prediction only — and none was generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This submission contains 10 distinct chemical or botanical ingredients listed as a single drug string:
ARNICA MONTANA WHOLE · ARSENIC TRIOXIDE · AVISCUMINE · BARIUM IODIDE · CLAVICEPS PURPUREA SCLEROTIUM · OYSTER SHELL CALCIUM CARBONATE (CRUDE) · PHOSPHORUS · SILVER NITRATE · SOLANUM NIGRUM TOP · TOBACCO LEAF
The TxGNN pipeline is designed to evaluate individual drug entities mapped to DrugBank IDs. Because this submission could not be resolved to any single DrugBank entry (drugbank_id: null), the knowledge graph traversal and deep learning prediction steps both returned empty results.
Notably, several components individually have known pharmacological profiles — for example, Arsenic Trioxide is an established antineoplastic agent used in Acute Promyelocytic Leukemia (APL), and Aviscumine (mistletoe lectin) has been investigated as an immunotherapy adjuvant. However, the combination as a whole remains uncharacterized in standard drug databases.
The ingredient profile (Phosphorus, Arsenic Trioxide, Silver Nitrate, botanical extracts) is consistent with homeopathic or complex traditional medicine formulations, which typically fall outside the scope of conventional repurposing pipelines.
Safety Considerations
No safety data is currently available for this compound as a combined entity. Individual components carry significant standalone risks:
- Arsenic Trioxide: Known QT-prolongation risk, hepatotoxicity, and hematological toxicity; requires cardiac monitoring
- Silver Nitrate: Corrosive at high concentrations; argyria risk with chronic exposure
- Claviceps Purpurea (Ergot): Vasoconstrictive alkaloids; contraindicated in vascular disease and pregnancy
- Tobacco Leaf: Nicotine-containing; cardiovascular and addiction risk
Please refer to individual component package inserts for component-level safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The compound cannot be evaluated through standard TxGNN repurposing methodology because it is a multi-ingredient mixture without a unified DrugBank identity, no approved indications, and no regulatory registrations. Proceeding would require fundamental disambiguation of the compound’s identity and intended use.
To proceed, the following is needed:
- Clarify compound identity — Determine whether this is a registered formulation (e.g., a homeopathic product with a specific product code) or an experimental combination; provide the intended product name or registration number
- Decompose into individual agents — If repurposing evaluation is desired, submit each active ingredient (especially Arsenic Trioxide and Aviscumine) as separate pipeline candidates with their individual DrugBank IDs
- Establish a primary indication — Document the intended or historical therapeutic use of this combination to anchor the repurposing comparison
- Resolve MOA data gaps — Obtain mechanism-of-action data (DG002) and package insert warnings (DG001) for at minimum the pharmacologically active components
- Regulatory feasibility check — Confirm whether the combination formula has any registration pathway under Taiwan FDA or US FDA before investing further in evidence collection
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.